Summary of minutes of EUCAST Steering Committee Meeting
Dusseldorf, Germany 11-12 February 2014

Attending
Dr Derek F.J. Brown
Dr Rafael Cantón
Prof Luc Dubreuil
Dr Christian Giske
Prof Gunnar Kahlmeter
Prof Luis Martinez-Martínez
Prof Johan W. Mouton
Prof Sören Gatermann
Dr Martin Steinbakk
Dr Robert Skov

DB  Scientific Secretary  United Kingdom
RC  Chairperson  Spain
LD  CA-SFM  France
CG  SRGA  Sweden
GK  Clinical Data Co-ordinator  Sweden
AM  BSAC  United Kingdom
LM  EUCAST General Committee  Spain
JM  CRG  The Netherlands
SG  EUCAST General Committee  Germany
MS  NWGA  Norway
RS  EUCAST General Committee  Denmark

1  Chairman’s welcome
2  Minutes of meeting of 25-26 November 2013  The minutes were accepted as a correct record.
3  Matters arising from minutes of 23-24 September 2013 (items not covered by agenda)  None.
4  New agents  The EMA have given a positive opinion on bedaquiline, breakpoints are S ≤0.25, R >0.25 mg/L. There will be a separate section for anti-mycobacterial agents on the EUCAST website.
5  EUCAST rationale documents  Ceftaroline and ceftobiprole documents are being prepared.
6  Subcommittees  The Antifungal Susceptibility Testing (AFST) Steering Committee structure has been revised. A technical note for Candida with micafungin, anidulafungin and fluconazole was published in Mycology. Breakpoints for posaconazole and Aspergillus are higher in the SmPC than set by the AFST subcommittee. A paper on detection of resistance mechanisms of clinical and/or epidemiological importance has been published on the EUCAST website.
7  Breakpoint issues  Breakpoint tables, version 4.0, have been published on the EUCAST website. In future versions horizontal lines in the comments column will be removed within an antimicrobial group as comments often apply to more than one agent and the horizontal lines may be misinterpreted.

EUCAST does not have cefoxitin clinical breakpoints for Enterobacteriaceae and the cefoxitin zone diameter breakpoints are for screening for AmpC production only. If clinical data are provided in support of clinical use of cefoxitin to treat infections caused by Enterobacteriaceae it will be considered by the Steering Committee.

For coagulase-negative staphylococci and benzylpenicillin a line has been included with breakpoints as S “-“ and R “-“, together with a note that penicillinase production cannot be reliably detected.

Discrepancies in fidaxomycin MIC distributions for C. difficile are not resolved by additional data because MIC distributions are truncated.

Revision of ciprofloxacin breakpoints for N. meningitidis to S ≤ 0.03, R >0.03 mg/L are proposed.

Breakpoints of S ≤32 mg/L, R >32 mg/L for Enterobacteriaceae and amoxicillin-clavulanic acid in uncomplicated UTI have been added to breakpoint tables. MIC distributions for amoxicillin-clavulanic acid with a fixed 2 mg/L clavulanic acid will be separated from those with a 2:1 ratio on the MIC distribution website.

Sublactam breakpoints for Acinetobacter spp. are being considered.

It was noted that there is no robust clinical evidence regarding the activity of aminoglycosides and 1st/2nd generation cephalosporins against Salmonella and Shigella.
Evidence on the clinical significance of dissociated resistance to clindamycin is being collated. It is proposed that *Serratia marcescens* and aminoglycosides are removed from the EUCAST intrinsic resistance expert rule table.

A technical note explaining the issues with breakpoints for topical agents is being prepared.

A revision of EUCAST expert rules has been started.

Aztreonam breakpoints for *Pseudomonas* are being reviewed.

Breakpoints and susceptibility testing methodology for *N. gonorrhoeae* are being discussed.

Guidelines for manufacturers on data required for new antimycobacterial agents are being prepared.

Revised doripenem breakpoints are being implemented and breakpoints for other carbapenems are being reviewed.

The validity of the intermediate category for meropenem and cefotaxime for *S. pneumoniae* and *H. influenzae* in meningitis is being discussed.

It was reiterated that gentamicin breakpoints are not appropriate for *Listeria monocytogenes*.

Proposed changes to susceptibility testing methods and consequent breakpoints changes for telavancin were agreed.

Tigecycline breakpoints will be reviewed.

Following discussion of linezolid and metronidazole breakpoints the Steering Committee concluded that there are insufficient data to justify revision of breakpoints at present.

Nitroxoline breakpoints for Enterobacteriaceae in uncomplicated UTI will be considered.

Spiramycin and temocillin breakpoints will be considered.

It was agreed that EUCAST would not provide recommendations for fluoroquinolones for chronic prostatitis caused by *E. faecalis*.

Data on use of daptomycin for enterococcal infections is being collected.

A European veterinary initiative on antimicrobial resistance was discussed.

Data suggesting that ciprofloxacin, moxifloxacin, levofloxacin and norfloxacin were equivalent for *Corynebacterium* spp. were felt to be inadequate to support recommendations on equivalence.

The clinical significance of the ampicillin/amoxicillin intermediate category for *S. pneumoniae* is being assessed.

A list of organism-agent combinations lacking clinical data to support breakpoints will be released on the EUCAST website.

### Organisms without EUCAST breakpoints

A guidance note on recommendations for testing *Actinomyces* spp. will be prepared.

### EUCAST methods

The 24h incubation time for glycopeptide susceptibility tests on enterococci was confirmed.

Control ranges are being established for *H. influenzae* ATCC 49766 to replace NCTC 8648.

Updated versions of the disk diffusion manual, slide show and reading guide are being prepared.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Zone diameter data are being collected from volunteer laboratories to establish ECOFFs for <em>Salmonella</em> and <em>Campylobacter</em>:</td>
<td></td>
</tr>
<tr>
<td>10 <strong>Implementation of EUCAST breakpoints</strong> The “compliance of manufacturers” file on the EUCAST website has been updated.</td>
<td></td>
</tr>
<tr>
<td>11 <strong>EUCAST websites</strong> The frequently asked questions section has been revised. “Translations” and “contacts” links have been added to the contents list on the EUCAST pages. A “warnings” section has been added to the susceptibility testing section so that significant problems with particular products can be listed. All the files in the calibration and validation section have been updated. It is unclear how the international MIC distribution website will progress as CLSI do not agree to the site being freely available and CLSI veterinary and antifungal groups may produce their own database.</td>
<td></td>
</tr>
<tr>
<td>12 <strong>Publications and presentations</strong> Papers explaining ECOFFs and reporting as tested for Enterobacteriaceae are being prepared. A paper on calibration and validation of the EUCAST disk diffusion method has been accepted for publication in CMI. A paper on uptake of EUCAST breakpoints has been submitted for publication in Eurosurveillance.</td>
<td></td>
</tr>
<tr>
<td>13 <strong>NACs</strong> Both South Africa and Slovenia are setting up NACs.</td>
<td></td>
</tr>
<tr>
<td>14 <strong>EUCAST SOPs</strong> SOP 7.0 on EUCAST minutes has been released on the website. An SOP on update and format of EUCAST documents (SOP 8.0) is being prepared.</td>
<td></td>
</tr>
<tr>
<td>15 <strong>ESCMID</strong> ECCMID 2014 will include a susceptibility testing workshop and a meet the experts session on EUCAST frequently asked questions. A Postgraduate Educational Course will be held in Linz, Tuesday 16 – Friday 19 September 2014:</td>
<td></td>
</tr>
<tr>
<td>16 <strong>EMA</strong> No new information.</td>
<td></td>
</tr>
<tr>
<td>17 <strong>ECDC</strong> The specific contract for the period to September 2014 has been signed. There will be a new ECDC tender for the period from October 2014 – 2017.</td>
<td></td>
</tr>
<tr>
<td>18 <strong>CLSI</strong> GK and RS reported on the CLSI meeting in January.</td>
<td></td>
</tr>
<tr>
<td>19 <strong>Any other business</strong> Recommendations on generation and reporting of statistics on bacterial resistance will be considered.</td>
<td></td>
</tr>
<tr>
<td>20 <strong>Next meetings</strong> 7-8 July 2014, Stockholm, Sweden. 15-16 September 2014, Linz, Austria (before ESCMID Postgraduate Workshop). 10-11 November 2014, Basel, Switzerland. 16-17 February 2015, Brussels, Belgium. 28-29 April 2015, Copenhagen, Denmark (immediately following ECCMID).</td>
<td></td>
</tr>
</tbody>
</table>